# Pizarra — PT-pseudo_dd011d696387 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dd011d696387
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 75-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.372 ng/mL²
  - PSA velocity: 0.55 ng/mL/yr
  - Prior PSA: 14.0 ng/mL
  - Prostate volume: 26.91 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8577571 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Coronary artery disease, Benign prostatic hyperplasia
  - Current medication: atorvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 27 mL. csPCa 0.86.

Vitals: weight 92 kg, height 179 cm, BMI 28.7, BP 101/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2002).

Chief complaint: Clinical attention sought for reassessment of a previously confirmed prostate malignancy alongside recent fluctuations in prostate-specific antigen levels.

History: Clinical review initiated to reassess a previously established prostate cancer diagnosis. At 75 years of age, he works as an active dairy farmer and resides independently as a widower, relying on his adult daughter as his main point of contact. Body mass indexes 28.7 at a weight of 92 kg. Tobacco use ceased in 2002, accounting for a cumulative 13 pack-year exposure. Chronic coronary artery disease remains controlled via atorvastatin, while tamsulosin addresses benign prostatic hyperplasia; lower urinary tract symptoms are negligible, scoring just 2 on the IPSS scale. Daily life centers around agricultural work, with otherwise limited physical activity. Alcohol intake stays around three units weekly. Public transit limitations dictate a preference for morning visits. A decades-old meniscal injury occasionally flares during wet conditions, and he maintains routine cardiology appointments solely for blood pressure tracking. Unexplained weight reduction, skeletal discomfort, and blood in the urine are firmly denied, as he prioritizes continuing his agricultural schedule. December 2024 bloodwork revealed a prostate-specific antigen level of 10.0 ng/mL (free fraction 16%), complemented by unremarkable renal panels and complete blood counts. No medication sensitivities exist.

Physical examination: Digital rectal examination proves normal; the prostate presents as symmetrically enlarged with a smooth, firm consistency and absent nodules or asymmetry. Hemodynamic parameters show a blood pressure of 101/75 mmHg and a pulse of 73 beats per minute. Systemic assessment identifies a well-nourished individual exhibiting no signs of acute distress; pulmonary fields are clear and cardiac rhythm remains regular.

Patient info: active dairy farmer; Widowed; Lives alone; adult daughter is primary contact.
Next of kin: None recorded — patient declines to nominate.

Lifestyle: alcohol 3 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 2/35 (mild LUTS).


Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.59 +/- 0.20   (95% CI 0.20-0.92)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.4 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=10.0, age=75.0, psad=0.372, dre_ord=0.0, vol=26.91, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.55 ng/mL/yr) against the prior PSA (14.0 ng/mL) and the current PSA (10.0 ng/mL), which suggests a significant recent drop, and the PI-RADS 5 score. It also missed the context provided by the PSA history trend, which is crucial for interpreting the current level.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 59% probability of biopsy. This might be wrong because the prior biopsy status is 'Positive', which fundamentally changes the question from "Does he have cancer?" to "Is the cancer progressing/recurrent/new?" The high csPCa probability (0.8577571) combined with a PI-RADS 5 is high, but the prior positive biopsy status might make the decision to biopsy less urgent or change the interpretation of the current findings.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or high-risk features not captured by PI-RADS 5, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the trend shows a significant rise despite the current PSA of 10.0 ng/mL, it would strongly argue for biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or follow-up plan that informs the current reassessment.
  <document> laboratory panel -> This panel might contain information on PSA free fraction or other markers that modify the interpretation of the PSA level.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  UMCG Radiology | 08 Jan 2025 | Multiparametric MRI Prostate
  Clinical Context: Assessment of previously identified malignancy. Recent serum prostate-specific antigen stands at 10.0 ng/mL (velocity 0.55 ng/mL/yr); baseline imaging carried a PI-RADS 5 designation.
  FINDINGS:
  Glandular dimensions register 26.91 mL. T2-weighted sequences disclose a discrete hypointense focus within the left peripheral zone at the base/mid-gland level, spanning roughly 14 mm. High b-value diffusion-weighted imaging exhibits pronounced restriction with matching low apparent diffusion coefficient values. Dynamic contrast enhancement demonstrates early, localized uptake compared to adjacent tissue. Capsular integrity remains intact; seminal vesicles are clear. Pelvic nodal basins appear normal. Skeletal structures lack suspicious marrow signal.
  IMPRESSION:
  PI-RADS 5 lesion in the left peripheral zone measuring approximately 14 mm. Prostate volume 26.91 mL yielding a PSA density of 0.372 ng/mL/mL. csPCa predicted probability 0.8577571.

  **psa_trend**
  [{"date": "Nov 2023", "val": 2.9}, {"date": "Mar 2024", "val": 1.2}, {"date": "Jun 2024", "val": 4.6}, {"date": "Sep 2024", "val": 8.7}, {"date": "Jan 2025", "val": 10.0}]

  **previous_notes**
  [{"date": "16 May 2024", "author": "Dr. M. Jansen (GP)", "text": "Annual wellness visit. Occasional nighttime voiding reported; otherwise asymptomatic. Initial prostate-specific antigen measurement measured 6.2 ng/mL. Follow-up testing scheduled for six months later to monitor the sustained elevation."}, {"date": "21 Jul 2023", "author": "Dr. M. Jansen (GP)", "text": "March 2024 follow-up shows PSA holding at 7.5 ng/mL. Mild daytime frequency noted without notable obstruction. Urology consultation arranged to investigate the ongoing marker elevation alongside earlier positive biopsy results."}]

  **lab_results**
  [{"name": "PSA", "val": "10.0 ng/mL", "date": "16 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.61 ng/mL", "date": "16 Dec 2024", "flag": "L"}, {"name": "%Free PSA", "val": "16%", "date": "16 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.3 g/dL", "date": "16 Dec 2024", "flag": ""}, {"name": "WBC", "val": "7.0 x10^9/L", "date": "16 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "221 x10^9/L", "date": "16 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "107 umol/L", "date": "16 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "16 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "12.7 nmol/L", "date": "16 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "73 U/L", "date": "16 Dec 2024", "flag": ""}, {"name": "LDH", "val": "199 U/L", "date": "16 Dec 2024", "flag": ""}]

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left peripheral zone measuring approximately 14 mm
  PSA velocity of 0.55 ng/mL/yr
  PSA trend shows a rise from 1.2 ng/mL (Mar 2024) to 10.0 ng/mL (Jan 2025)
  csPCa predicted probability 0.8577571

  AGAINST sampling this patient now:
  Prior biopsy status: Positive

WHERE THIS LEANS
  The retrieved evidence strongly argues for further investigation due to the high-risk MRI finding (PI-RADS 5) and the rising PSA trend, which contradicts the negative implication of the prior positive biopsy. This leans towards recommending biopsy to assess progression or recurrence.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports further investigation due to the high-risk PI-RADS 5 lesion (14 mm) and the rising PSA trend, which contradicts the prior positive biopsy status. The PSA trend shows a significant rise from 1.2 ng/mL (Mar 2024) to 10.0 ng/mL (Jan 2025), and the PI-RADS 5 finding warrants sampling to assess for progression or recurrence.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
